Y-mabs files for EU approval for pediatric cancer drug

On Tuesday, Danish biotech firm Y-mabs submitted an application to get approval for the cancer drug omburtamab, according to the firm.


US-Danish Biotech firm Y-mabs, which is listed on US Stock Exchange Nasdaq, has submitted a new application for marketing authorization for a cancer treatment. This was revealed after the close of trading on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs